文献速递头颈PETCT

基于PET/CT确定转移性鼻咽癌患者是否适合接受根治性放疗:一项大型队列研究

Determining the suitability of definitive radiation therapy in patients with metastatic nasopharyngeal carcinoma based on PET/CT: a large cohort study.
PubMed 文献 · Eur Radiol · 2022-05-04

该研究纳入570例初诊转移性鼻咽癌患者,接受姑息化疗或姑息化疗联合根治性放疗,采用化疗后Deauville评分和EBV DNA进行递归分区分析风险分层。结果显示,低危和中危组接受联合根治性放疗的无进展生存率显著优于单纯化疗,而高危组未见获益。

要点

  • 化疗后Deauville评分1-3分与4-5分患者2年无进展生存率分别为23.4%和8.5%,差异有统计学意义(p<0.001)。
  • 递归分区分析将患者分为RPA I、II、III三组,RPA I和II组化疗后Deauville评分均在1-3分范围内。
  • RPA I和II组接受姑息化疗联合根治性放疗较单纯姑息化疗显著改善无进展生存率,RPA III组未见此获益。

核心结论

  • 在初诊转移性鼻咽癌患者中,姑息化疗联合根治性放疗可能改善低危和中危组患者的生存率,但高危组患者未获益。

研究设计与样本

  • 大型队列研究,纳入570例初诊转移性鼻咽癌患者,接受姑息化疗或姑息化疗联合根治性放疗,采用化疗后Deauville评分和EBV DNA水平进行递归分区分析风险分层。

关键影像表现/征象

  • 化疗后Deauville评分1-3分与4-5分患者2年无进展生存率分别为23.4%和8.5%,差异有统计学意义(p<0.001)。
  • 化疗后Deauville评分1-3分与4-5分患者2年总生存率分别为56.8%和18.8%,差异有统计学意义(p<0.001)。

诊断标准与关键数值

  • RPA I组:治疗前EBV DNA≤4000 copies/mL且化疗后检测不到。
  • RPA II组:治疗前EBV DNA>4000 copies/mL,或治疗前EBV DNA≤4000 copies/mL但化疗后可检测到。
  • RPA III组:Deauville评分4-5分。
  • RPA I组接受姑息化疗联合根治性放疗与单纯姑息化疗的无进展生存率分别为72.7%和13.4%。
  • RPA II组接受姑息化疗联合根治性放疗与单纯姑息化疗的无进展生存率分别为37.8%和6.3%。

临床应用与阅片要点

  • 化疗后Deauville评分和EBV DNA水平可用于对初诊转移性鼻咽癌患者进行风险分层,辅助判断是否从联合根治性放疗中获益。
  • 低危和中危组患者接受姑息化疗联合根治性放疗可能改善无进展生存率,高危组患者未见此获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To determine patients with de novo metastatic nasopharyngeal carcinoma (mNPC) who would benefit from receiving definitive radiation therapy (DRT) along with their pre-existing palliative chemotherapy (PCT) by evaluating their post-PCT Deauville scores and EBV DNA.

METHODS: A total of 570 mNPC patients, treated with PCT or PCT+DRT, were studied. EBV DNA levels, along with post-PCT Deauville scores, were used to stratify risk based on the recursive partitioning analysis (RPA).

RESULTS: Significant differences were observed in the survival rates of patients with Deauville scores of 1-3 and 4-5 (2-year progression-free survival (PFS): 23.4% versus 8.5%, p < 0.001; 2-year overall survival (OS): 56.8% versus 18.8%, p < 0.001). RPA yielded three distinct groups in the increasing order of risk (Deauville scores of all RPA I-II were within the range of 1-3): (1) RPA I: EBV DNA levels at a pretreatment concentration ≤ 4000 copies/mL and undetectable post-PCT; (2) RPA II: EBV DNA levels either at a pretreatment concentration > 4000 copies/mL or at a pretreatment concentration ≤ 4000 copies/mL and detectable post-PCT; (3) RPA III: Deauville scores 4-5. While patients in RPA I and RPA II had significantly PFS rates when treated with PCT+DRT than when treated with PCT alone (RPA I: 72.7% versus 13.4%, RPA II: 37.8% versus 6.3%), those in RPA III did not experience such PFS benefits (6.5% versus 9.7%).

CONCLUSION: PCT+DRT might improve the survival rates in mNPC patients in the low- and mid-risk strata but not those of patients in the high-risk strata.

KEY POINTS: We use the Deauville scores and the concentrations of the Epstein-Barr virus (EBV) DNA to determine those patients with de novo metastatic NPC who would benefit from radiation therapy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Yang, Hu, Liu, et al. Determining the suitability of definitive radiation therapy in patients with metastatic nasopharyngeal carcinoma based on PET/CT: a large cohort study. Eur Radiol. 2022. PMID: 35505116. doi:10.1007/s00330-022-08814-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。